Advertisement
Life-Sciences-USA.com
The Transatlantic Life Sciences Web Portal
This is a free web portal for the life sciences in North America, Europe and Israel... » read more
- Genentech Acquires CDK Inhibitors from Regor: $850m Upfront (2024-09-30)
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones Cambridge, M... - Flagship Pioneering Unveils Mirai Bio and Commits $50m (2024-09-26)
> Mirai’s machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries > Co-optimization of cargo design and manufacturing ensure the best possible medicine and manufactu... - Tempus Expands Oncology Collaboration with Takeda (2024-09-26)
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and develop... - Generate:Biomedicines & Novartis: Multi-target Collaboration (2024-09-24)
Potential total transaction valued at more than $1 billion with $65 million in total upfront consideration Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutic... - Launch of Aptadir Therapeutics to Develop RNA Inhibitors (2024-09-24)
> A novel approach for intractable cancers and genetic conditions > Science originates from 3 top international institutions – the Beth Israel Deaconess Medical Center of the Harvard Medical School, the Italian Research National Council (CNR) and the Cancer Sc... - Altaris to Acquire Minaris Regenerative from Resonac Corp (2024-09-24)
Resonac Corporation (President: Hidehito Takahashi, hereinafter called “REC”), announces that it has entered into a definitive share purchase agreement (hereinafter called “this deal”) to transfer all of the issued shares in Minaris Regenerative Medicine, L... - Minaris Regenerative Medicine to Be Acquired by Altaris (2024-09-24)
Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris t... - Constructive Bio Secures $58min Series A Financing (2024-09-24)
> Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years > Paladin Capital, Fine Structure Ventures, +ND Capital and Abcam-founder Jonathan Milner join as new investors > Sir Gre... - Andreas Eckert on the IPO of Pentixapharm at FSE – Interview (2024-09-24)
First German Life Sciences IPO since 2016 – Radiopharma Company Pentixapharm Lists at Frankfurt Stock Exchange A dewy interview by |transkript.de/Georg Kääb with Andreas Eckert, Chair of Pentixapharm and major shareholder of Eckert & Ziegler AG Pentixa... - Egle Gedrimaite to Head Business Development at Cosmo (2024-09-23)
Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosm...
Life-Sciences-USA.com is your doorway to the Transatlantic life sciences!
[LSUS] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in the North America, Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSUS] is 100% Made in Germany!
» Start here with the latest News!Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top